Preliminary clinical trials have demonstrated that radiolabeled anti-CD20 monoclonal antibodies can achieve remissions in 65-90% of lymphoma patients failing chemotherapy. However, most patients treated with conventional radiolabeled antibodies (RAb) subsequently relapse and die of recurrent lymphoma. The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional RIT. Two separate pretargeting approaches will be investigated, one using streptavidin (SA) and radioactive biotin and the second employing molecularly engineered bispecific anti-CD20 x anti-ligand antibodies which bind covalently to radiolabeled ligands. First, we will compare the in vivo biodistribution, radiation dosimetry, and therapeutic efficacy of pretargeted ?-emitting radionuclides (90Y, 177Lu) with pretargeted ?-emitters (213Bi, 211At) and with conventional RIT in murine xenograft models. Second, we will employ novel new digital autoradiographic methods to perform small scale microdosimetry of alpha-emitters deposited in tumor micro- clusters and xenografts with either conventional RIT or pretargeted RIT (PRIT) and correlate these findings with observed tumor eradication rates. Third, we will evaluate the pharmacokinetics, biodistributions, toxicities and efficacies of novel, molecularly designed bispecific anti-CD20 x anti-ligand Abs which possesses a molecularly engineered binding pocket capable of binding covalently to synthetic radiolabeled electrophilic ligands. These bispecific anti-CD20 x anti-ligand Abs will be compared directly to the SA-biotin pretargeting approach in lymphoma models. Finally, we will investigate potential synergy of novel new small molecule inhibitors of Bruton tyrosine kinase (ibrutinib), PI3 kinase-delta (idelalisib), and BH3-mimetics (ABT-199) with PRIT using both ? and ? emitters. We hypothesize that the pretargeting strategies defined in this proposal will improve the tumor-to-normal organ ratios of absorbed radiation compared with conventional RIT, allowing improvement in response rates and response durations with less toxicity than is currently feasible. We hypothesize that pretargeting will eliminate the necessity of administering myeloablative doses of 131I- or 90Y- labeled anti-CD20 Ab with hematopoietic stem cell rescue to achieve maximal response rates and survival rates. We anticipate rapid translation of the results of these preclinical experiments into our clinical RIT program for human Non-Hodgkin's lymphomas.

Public Health Relevance

Approximately 75,000 Americans are expected to develop Non-Hodgkin Lymphoma in 2014 and less than half will be cured with conventional treatments. Radiolabeled monoclonal antibodies targeting the CD20 antigen expressed on the surface of most lymphomas are effective at inducing remissions even after failure of standard chemotherapy and radiotherapy. This grant proposal describes the development of several innovations that markedly improve the effectiveness and decrease the toxicity of radiolabeled antibody therapy for lymphomas.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Prasanna, Pat G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Palanca-Wessels, Maria Corinna; Press, Oliver W (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123:2293-301
Green, Damian J; Orgun, Nural N; Jones, Jon C et al. (2014) A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res 74:1179-89
Procko, Erik; Berguig, Geoffrey Y; Shen, Betty W et al. (2014) A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell 157:1644-56
Gopal, Ajay K; Gooley, Ted A; Rajendran, Joseph G et al. (2014) Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ? 60 years with B cell lymphoma. Biol Blood Marrow Transplant 20:770-5
Matesan, Manuela; Rajendran, Joseph; Press, Oliver W et al. (2014) 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl Med Commun 35:1132-42
Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M et al. (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-20
Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M et al. (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res 19:6624-32
Pagel, John M; Kenoyer, Aimee L; Back, Tom et al. (2011) Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118:703-11
Park, Steven I; Shenoi, Jaideep; Frayo, Shani M et al. (2011) Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res 17:7373-82
Gunn, Jonathan; Park, Steven I; Veiseh, Omid et al. (2011) A pretargeted nanoparticle system for tumor cell labeling. Mol Biosyst 7:742-8

Showing the most recent 10 out of 42 publications